Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region

Overview

Pancreatic Neuroendocrine tumors and carcinomas (pNET) see the last year their incidence and prevalence going up. On the basis of their grade of differentiation and proliferation ratio measured Ki67 staining, there are divided into 3 grade groups : Grade 1 with Ki67 between 1 and 3%, Grade 2 between 3 and 20% and well-differentiated neuroendocrine grade tumors 3 with KI67 greater than 20%, so undifferentiated carcinomas. pNET is a heterogenous group of tumors with variable prognosis. The aim of this study is to identify the prognostic factors in this population, as well the place of neutrophil-to-lymphocyte ratio as a prognostic marker. The primary endpoint is the description of clinic and pathological parameters of patients from Alsace. The secondary endpoints are the identification of prognostic factors in this population

Full Title of Study: “Clinicopathological Assessment of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: June 2020

Clinical Trial Outcome Measures

Primary Measures

  • The survival will be evaluated by Kaplan Meier Method. The prognostic factors will be evaluated with univariate and multivariate analysis by Cox regression model.
    • Time Frame: The participant will be followed-up for a maximum of 11 years, and 1 year at least.

Participating in This Clinical Trial

Inclusion Criteria

1. Major topic ((≥18 years) 2. Subject with histologically confirmed pancreatic neuroendocrine tumor or carcinoma 3. Subject with tumours or neuroendocrine carcinoma of the pancreas at any stage of the disease. 4. Subject covered in one of the participating centres between 01/01/2008 and 01/01/2019 5. Have a pre-therapeutic biological check-up 6. Subject who has not expressed opposition to the use of his or her data for research purposes Exclusion criteria:

1. Subject who expressed opposition to participate in the study 2. Lack of histological data 3. Minor subject 4. Patient under the protection of justice 5. Subject under guardianship or trusteeship

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Strasbourg, France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Gabriel MALOUF, MD, PhD, 33 3 88 11 62 22, gabriel.malouf@chru-strasbourg.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.